A comment on metformin and COVID-19 with regard to "Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID-19 patients with diabetes: A population-based study in Lombardy".

Al-Salameh, Abdallah; Wiernsperger, Nicolas; Cariou, Bertrand; Lalau, Jean-Daniel

Al-Salameh, Abdallah; Wiernsperger, Nicolas; Cariou, Bertrand; Lalau, Jean-Daniel.

Al-Salameh A; Department of Endocrinology-Diabetes Mellitus and Nutrition, Amiens University Hospital, Amiens, France.
Wiernsperger N; PériTox, UMR-I 01, University of Picardie Jules Verne, Amiens, France.
Cariou B; Association REMEDES, Ville-sur-Jarnioux, France.
Lalau JD; Département d'Endocrinologie, Diabétologie et Nutrition, l'institut du thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, Nantes Cedex 01, France.

Diabetes Obes Metab ; 24(9): 1888-1893, 2022 09.

Article in English | MEDLINE | ID: covidwho-1840394

Subject(s)

COVID-19; Diabetes Mellitus, Type 2; Metformin; COVID-19/epidemiology; Diabetes Mellitus, Type 2/complications; Diabetes Mellitus, Type 2/drug therapy; Diabetes Mellitus, Type 2/epidemiology; Hospitalization; Humans; Hypoglycemic Agents/adverse effects; Metformin/therapeutic use; Retrospective Studies; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / COVID-19 / Metformin Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Diabetes Obes Metab Journal subject: Endocrinology / Metabolism Year: 2022 Document Type: Article Affiliation country: Dom.14746

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google